Corona Remedies Reports 15.1% YoY Revenue & 21.8% PAT Growth in Q2FY26
Filing Summary
Corona Remedies Limited announced its Q2FY26 financial results, reporting a consolidated revenue from operations of ₹361 Cr, marking a 15.1% year-on-year increase. The company’s profit after tax (PAT) for the quarter was ₹52 Cr, reflecting a 21.8% growth compared to the previous year. For the half-year ending September 30, 2025, the revenue was ₹708 Cr, with a PAT of ₹99 Cr, showing a 35.1% year-on-year increase. The company will conduct an earnings call on January 05, 2026, to discuss these results further.
Corona Remedies Limited has released its financial results for the second quarter of the fiscal year 2026. The company reported a consolidated revenue from operations of ₹361 Cr for Q2FY26. This represents a 15.1% increase compared to the same quarter in the previous year. For the half-year period ending September 30, 2025, the revenue was ₹708 Cr, showing a 17.0% year-on-year growth.
The profit after tax (PAT) for Q2FY26 was ₹52 Cr, which is a 21.8% increase from the previous year. For the half-year period, the PAT was ₹99 Cr, reflecting a 35.1% growth year-on-year. The EBITDA for the quarter was ₹78 Cr, with an EBITDA margin of 21.7%. For the half-year, the EBITDA was ₹148 Cr, with a margin of 20.9%.
In terms of operational metrics, the company reported a gross profit of ₹292 Cr for Q2FY26 and ₹573 Cr for the half-year. The profit after tax margin stood at 14.5% for the quarter and 13.9% for the half-year. The company also reported a return on equity (RoE) of 31.1% and a return on capital employed (RoCE) of 49.7% for the half-year, both annualized figures.
The company has scheduled an earnings call on January 05, 2026, at 12:00 PM IST to discuss these financial results and the business performance for the quarter. Interested parties can participate in the call by dialing the provided numbers.
Corona Remedies Limited is an India-focused pharmaceutical company engaged in developing, manufacturing, and marketing products in various therapeutic areas, including women’s healthcare, cardio-diabeto, and pain management. The company operates WHO-GMP/ EU GMP-certified manufacturing facilities and has two DSIR-approved R&D centers. Corona Remedies employs over 4500 individuals and focuses on maintaining international quality standards in its healthcare solutions.